AAIC 2025 Abstract
Phase 1b/2a, 6‐month, randomized, double‐blind, placebo‐controlled study of the safety/tolerability and preliminary evidence of efficacy of a tau‐targeted therapeutic in patients with corticobasal syndrome
Abstract
Background: Corticobasal syndrome (CBS) is a devastating and untreatable neurodegenerative disease that interferes with cognition, movement, and behavior, and only a handful of clinical trials have been conducted in this population.
